The active ingredient of Yamadin®20 and Yamadin®40 tablet is Famotidine. Famotidine is a novel, highly specific and potent competitive H2- receptor antagonist. It has a rapid onset and prolonged duration of action. Famotidine reduces the acid and pepsin content, as well as the volume of basal, nocturnal and stimulated gastric secretion. Yamadin® tablet is indicated in short term treatment of active duodenal ulcer and benign gastric ulcer, maintenance therapy for prevention of relapses of duodenal ulceration, gastro-oesophageal reflux disease and Zollinger-Ellison Syndrome.
Yamadin Tablet 40 mg
Duodenal ulcer: 40 mg at night for 4 to 8 weeks
Benign gastric ulcer: 40 mg at night for 4 to 8 weeks; Maintenance therapy: 20 mg at night for preventing the recurrences of duodenal ulceration
Gastro-oesophageal reflux disease: 20 mg twice daily for 6 to 12 weeks
Zollinger Ellison syndrome: The recommended starting dose is 20 mg every six hours. Dosage should then be adjusted to individual response. Doses up to 160 mg every six hours have been administered to some patients without the development of significant adverse effects
Dosage can be administered irrespective of meals. Antacids may be given concomitantly if needed.